These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 25938351)
21. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215 [TBL] [Abstract][Full Text] [Related]
22. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis. Hale CS; Qian M; Ma MW; Scanlon P; Berman RS; Shapiro RL; Pavlick AC; Shao Y; Polsky D; Osman I; Darvishian F Am J Surg Pathol; 2013 Jun; 37(6):882-9. PubMed ID: 23629443 [TBL] [Abstract][Full Text] [Related]
23. Interobserver variability of mitotic index and utility of PHH3 for risk stratification in gastrointestinal stromal tumors. Alkhasawneh A; Reith JD; Toro TZ; Ayed AO; Lu X; George TJ; Duckworth LV Am J Clin Pathol; 2015 Mar; 143(3):385-92. PubMed ID: 25696796 [TBL] [Abstract][Full Text] [Related]
24. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors. Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845 [TBL] [Abstract][Full Text] [Related]
25. Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting. Harvey J; Thomas C; Wood B; Hardie M; Dessauvagie B; Combrinck M; Frost FA; Sterrett G Pathology; 2015 Jan; 47(1):13-20. PubMed ID: 25474507 [TBL] [Abstract][Full Text] [Related]
26. Invasive lobular carcinoma of the breast: assessment of proliferative activity using automated Ki-67 immunostaining. Dessauvagie B; Thomas A; Thomas C; Robinson C; Combrink M; Budhavaram V; Kunjuraman B; Meehan K; Sterrett G; Harvey J Pathology; 2019 Dec; 51(7):681-687. PubMed ID: 31630876 [TBL] [Abstract][Full Text] [Related]
27. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study. Chow KL; Tse KY; Cheung CL; Wong KW; Cheung AN; Wong RW; Chan AN; Yuen NW; Ngan HY; Ip PP Histopathology; 2017 Apr; 70(5):746-755. PubMed ID: 27864989 [TBL] [Abstract][Full Text] [Related]
28. Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors. Pang SJ; Li CC; Shen Y; Liu YZ; Shi YQ; Liu YX Int J Clin Exp Pathol; 2015; 8(5):4418-26. PubMed ID: 26191133 [TBL] [Abstract][Full Text] [Related]
29. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ. Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232 [TBL] [Abstract][Full Text] [Related]
30. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Tsuta K; Liu DC; Kalhor N; Wistuba II; Moran CA Am J Clin Pathol; 2011 Aug; 136(2):252-9. PubMed ID: 21757598 [TBL] [Abstract][Full Text] [Related]
31. Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors. Kim MJ; Kwon MJ; Kang HS; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Park HC Biomed Res Int; 2018; 2018():1013640. PubMed ID: 29780816 [TBL] [Abstract][Full Text] [Related]
32. Phospho-histone-H3 immunostaining for pulmonary carcinoids: impact on clinical appraisal, interobserver correlation, and diagnostic processing efficiency. Laflamme P; Mansoori BK; Sazanova O; Orain M; Couture C; Simard S; Trahan S; Manem V; Joubert P Hum Pathol; 2020 Dec; 106():74-81. PubMed ID: 33007357 [TBL] [Abstract][Full Text] [Related]
33. Potential Pitfalls in Diagnostic Digital Image Analysis: Experience with Ki-67 and PHH3 in Gastrointestinal Neuroendocrine Tumors. Hacking SM; Sajjan S; Lee L; Ziemba Y; Angert M; Yang Y; Jin C; Chavarria H; Kataria N; Jain S; Nasim M Pathol Res Pract; 2020 Mar; 216(3):152753. PubMed ID: 31761497 [TBL] [Abstract][Full Text] [Related]
34. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index. Lea D; Gudlaugsson EG; Skaland I; Lillesand M; Søreide K; Søreide JA Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):499-505. PubMed ID: 33758143 [TBL] [Abstract][Full Text] [Related]
35. Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Casper DJ; Ross KI; Messina JL; Sondak VK; Bodden CN; McCardle TW; Glass LF Am J Dermatopathol; 2010 Oct; 32(7):650-4. PubMed ID: 20559123 [TBL] [Abstract][Full Text] [Related]
36. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3. Tracht J; Zhang K; Peker D J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471 [TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Kim YJ; Ketter R; Steudel WI; Feiden W Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279 [TBL] [Abstract][Full Text] [Related]
38. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas. Ramani P; Taylor S; Miller E; Sowa-Avugrah E; May MT J Histochem Cytochem; 2015 Jun; 63(6):397-407. PubMed ID: 25711230 [TBL] [Abstract][Full Text] [Related]
39. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer. Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949 [TBL] [Abstract][Full Text] [Related]
40. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients. Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]